FDA grants breakthrough device designation to Natera's multi-cancer blood test

▪ SCREENING

The investigational assay analyzes cell-free DNA to screen for multiple cancer types, including colorectal cancer, from a single blood sample; no MCED test has yet received FDA approval. (Targeted Oncology)